Journal Home > Volume 1 , Issue 4
Cancer Innovation 2022, 1(4): 344-347 https://doi.org/10.1002/cai2.38
Case Report | Open Access | Issue | Published: 04 December 2022

Pyrotinib‐associated acute kidney injury: A case report

Show Author's Information Kang Miao1,  Li Zhang1 ( ),  Xiaoyan Si1( )
Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China
Keywords:
pyrotinib, HER2 TKIs, acute kidney injury and case report
Cite this article:
Miao K, Zhang L, Si X. Pyrotinib‐associated acute kidney injury: A case report. Cancer Innovation, 2022, 1(4): 344-347. https://doi.org/10.1002/cai2.38
Download citation
EndNote(RIS)
BibTeX

327

Views

25

Downloads

Citations

0

Crossref

N/A

WoS

0

Scopus

N/A

CSCD

Abstract Full text About this article

Pyrotinib is a novel human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitor (TKI). Previous studies of pyrotinib showed that it is mainly excreted through the gastrointestinal tract rather than the kidneys, with little effect on renal function. Here, we report a patient with HER2‐mutated nonsmall cell lung cancer who developed acute kidney injury (AKI) after receiving pyrotinib treatment. This case alerts clinicians to the adverse renal effects of HER2 TKIs, especially in patients with chronic kidney disease. However, tumor treatment should remain a priority in clinical practice. In this case, AKI induced by pyrotinib was reversible. Therefore, there is no need to restrict the use of HER2 TKIs due to concerns about possible nephrotoxicity.


menu
Abstract
Full text
Outline
About this article

Pyrotinib‐associated acute kidney injury: A case report

Show Author's information Kang Miao1, Li Zhang1 ( ), Xiaoyan Si1( )
Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China

Abstract

Pyrotinib is a novel human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitor (TKI). Previous studies of pyrotinib showed that it is mainly excreted through the gastrointestinal tract rather than the kidneys, with little effect on renal function. Here, we report a patient with HER2‐mutated nonsmall cell lung cancer who developed acute kidney injury (AKI) after receiving pyrotinib treatment. This case alerts clinicians to the adverse renal effects of HER2 TKIs, especially in patients with chronic kidney disease. However, tumor treatment should remain a priority in clinical practice. In this case, AKI induced by pyrotinib was reversible. Therefore, there is no need to restrict the use of HER2 TKIs due to concerns about possible nephrotoxicity.

Keywords: pyrotinib, HER2 TKIs, acute kidney injury and case report

References(10)

Bylicki O, Paleiron N, Margery J, Guisier F, Vergnenegre A, Robinet G, et al. Targeting the PD‐1/PD‐L1 immune checkpoint in EGFR‐mutated or ALK‐translocated nonsmall‐cell lung cancer. Target Oncol. 2017;12(5):563–9.
DOI Google Scholar
Mazières J, Peters S, Lepage B, Cortot AB, Barlesi F, Beau‐Faller M, et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol. 2013;31(16):1997–2003.
DOI Google Scholar
Oh DY, Bang YJ. HER2‐targeted therapies ‐ a role beyond breast cancer. Nat Rev Clin Oncol. 2020;17(1):33–48.
DOI Google Scholar
Zhou C, Li X, Wang Q, Gao G, Zhang Y, Chen J, et al. Pyrotinib in HER2‐Mutant advanced lung adenocarcinoma after platinum‐based chemotherapy: a multicenter, open‐label, single‐arm, phase II study. J Clin Oncol. 2020;38(24):2753–61.
DOI Google Scholar
Cosmai L, Gallieni M, Porta C. Renal toxicity of anticancer agents targeting HER2 and EGFR. J Nephrol. 2015;28(6):647–57.
DOI Google Scholar
Liu Y, Zhang Q, Lu C, Hu W. Multiple administrations of itraconazole increase plasma exposure to pyrotinib in Chinese healthy adults. DDDT. 2021;15:2485–93.
DOI Google Scholar
Zhu Y, Li L, Zhang G, Wan H, Yang C, Diao X, et al. Metabolic characterization of pyrotinib in humans by ultra‐performance liquid chromatography/quadrupole time‐of‐flight mass spectrometry. J Chromatogr B. 2016;1033–1034:117–27.
DOI Google Scholar
Ozkok A, Edelstein CL. Pathophysiology of cisplatin‐induced acute kidney injury. BioMed Res Int. 2014;2014:1–17.
DOI Google Scholar
Seethapathy H, Zhao S, Chute DF, Zubiri L, Oppong Y, Strohbehn I, et al. The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors. Clin J Am Soc Nephrol. 2019;14(12):1692–700.
DOI Google Scholar
Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2‐positive advanced gastric or gastro‐oesophageal junction cancer (ToGA): a phase 3, open‐label, randomised controlled trial. Lancet. 2010;376(9742):687–97.
DOI Google Scholar
Publication history
Copyright
Acknowledgements
Rights and permissions

Publication history

Received: 02 September 2022
Accepted: 08 November 2022
Published: 04 December 2022
Issue date: December 2022

Copyright

© 2022 The Authors.

Acknowledgements

We would like to thank Professor Haiting Wu for providing the renal pathological imaging results.

Rights and permissions

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

Return